In a bold step towards global outreach, US-based startup Perpetua Life Biotech, a pioneer in the field of gerontology and longevity medicine, is delighted to announce the creation of Perpetua Life Biotech UK Ltd. This new UK subsidiary is set to enhance market accessibility locally and foster partnerships with British businesses and retailers.

Originating from Boston College in 2017 by three postgraduate biology students, Perpetua Life Biotech embarked on a mission to address the gap in the life extension market. Following intensive research and development, the company launched its leading product, AEON, in 2021. Dr. Michael Morgan, CEO of Perpetua Life Biotech, commented: “AEON was created to be an all-in-one longevity-focused supplement. Each compound chosen for its stand-alone benefits as well as its synergistic ones paired with the other 10”.

Dr. Morgan highlighted ongoing studies involving compounds such as Metformin, Low dose Naltrexone, and Rapamycin (Sirolimus), which show promising results in life extension.

Furthermore, food supplements like Nicotinamide Mononucleotide (NMN), Nicotinamide Riboside (NR), Trans-Resveratrol, Fisetin, Astragalus, Quercetin, and Spermidine are crucial, backed by over 1,000 published research papers demonstrating their anti-aging and anti-inflammatory benefits.

The recent development of establishing Perpetua Life Biotech UK Ltd. represents a strategic move to cater directly to the UK market. Previously, US-based operations faced challenges like extended delivery times and high customs fees for UK customers. The new UK base addresses these issues, offering British customers a more streamlined and cost-effective experience.

Already, Perpetua Life Biotech UK Ltd. is aiming for expansion into the EU for localised distribution, enhancing accessibility across Europe.

Dr. Michael Morgan, CEO, expressed excitement about this new venture, stating, “We are excited to embark on this new chapter for Perpetua Life Biotech with the establishment of Perpetua Life Biotech UK Ltd. The UK’s reputation as a hub for innovation in the life sciences aligns perfectly with our mission to create transformative biotechnological solutions.

Dr. Morgan concluded: “Despite very exciting developments in the anti-aging space we should not lose track of what can be done right now to fight the aging process and the benefits of regular exercise, fasting, good quality sleep, a healthy diet and the alleviation of stress should not be underestimated in its role to fight the aging process”.

Perpetua Life Biotech remains committed to advancing longevity research globally, and the launch of its UK entity underscores the company’s dedication to providing accessible and innovative solutions for healthy aging.

2024 is expected to continue bringing promising news from Perpetua Life for those interested in life extension research and advancements.

For more information, visit